department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Vonjo · pharmadog

pharmadog
drugs
Vonjo

drug

patient view →

pacritinib

Marketedupdated 2mo ago

by Sobi Inc

Approved

community read0 votes

all catalysts(6)

approval · 6

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

VONJO (PACRITINIB CITRATE) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Vonjo

generic

pacritinib

indication

Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 28, 2027

236 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Mar 25, 2030compositionUS 89808733.7y
Jan 17, 2029compositionUS 81536322.5y
May 5, 2028method-of-use (U-3331)US 95739641.8y

FDA exclusivities (2)

Feb 28, 2029ODE-397Orphan Drug (7y)2.6y
Feb 28, 2027NCENew Chemical Entity (5y)236d

Data sources

openFDA · ClinicalTrials.gov

last refreshed 57m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval24 co-mentions · 6 sources
drugVONJO24 co-mentions · 6 sources
tagSmall Molecule12 co-mentions · 6 sources

Trials studying pacritinib

phase2Pacritinib With Aza for Upfront Myelodysplastic Syndromenot yet recruitingn=25
phase2A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)recruitingn=78
phase2A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppressioncompletedn=40
phase2Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopeniasnot yet recruitingn=26
phase2Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemiarecruitingn=66
phase2Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasmsrecruitingn=27
phase3A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosisrecruitingn=399
phase2A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopeniarecruitingn=58

more trials →